Cargando…

Type and dose of gonadotropins in poor ovarian responders: does it matter?

Infertile patients with a diminished ovarian reserve, also referred to as poor ovarian responders, constitute a substantial and increasing population of patients undergoing in vitro fertilization. The management of patients with poor ovarian response is still a controversial issue. Almost a century...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudry, Liese, Racca, Annalisa, Tournaye, Herman, Blockeel, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243085/
https://www.ncbi.nlm.nih.gov/pubmed/34263173
http://dx.doi.org/10.1177/26334941211024203
_version_ 1783715698624692224
author Boudry, Liese
Racca, Annalisa
Tournaye, Herman
Blockeel, Christophe
author_facet Boudry, Liese
Racca, Annalisa
Tournaye, Herman
Blockeel, Christophe
author_sort Boudry, Liese
collection PubMed
description Infertile patients with a diminished ovarian reserve, also referred to as poor ovarian responders, constitute a substantial and increasing population of patients undergoing in vitro fertilization. The management of patients with poor ovarian response is still a controversial issue. Almost a century has passed since the introduction of the first gonadotropin. A broad collection of urinary and recombinant gonadotropins, including biosimilars, is commercially available now. Despite great advances in assisted reproductive technology, there remains uncertainty about the optimal treatment regimen for ovarian stimulation in poor ovarian responders. Although oocyte donation is the most successful and ultimate remedy for poor ovarian responders, most patients persist on using their own oocytes in several attempts, to achieve the desired pregnancy. The aim of this review is twofold: first, to provide an overview of the commercially available gonadotropins and summarize the available evidence supporting the use of one or another for ovarian stimulation in poor ovarian responders, and second, to address the controversies on the dosage of gonadotropins for this specific in vitro fertilization population.
format Online
Article
Text
id pubmed-8243085
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82430852021-07-13 Type and dose of gonadotropins in poor ovarian responders: does it matter? Boudry, Liese Racca, Annalisa Tournaye, Herman Blockeel, Christophe Ther Adv Reprod Health New insights into ART/IVF in Poor Ovarian Responders Infertile patients with a diminished ovarian reserve, also referred to as poor ovarian responders, constitute a substantial and increasing population of patients undergoing in vitro fertilization. The management of patients with poor ovarian response is still a controversial issue. Almost a century has passed since the introduction of the first gonadotropin. A broad collection of urinary and recombinant gonadotropins, including biosimilars, is commercially available now. Despite great advances in assisted reproductive technology, there remains uncertainty about the optimal treatment regimen for ovarian stimulation in poor ovarian responders. Although oocyte donation is the most successful and ultimate remedy for poor ovarian responders, most patients persist on using their own oocytes in several attempts, to achieve the desired pregnancy. The aim of this review is twofold: first, to provide an overview of the commercially available gonadotropins and summarize the available evidence supporting the use of one or another for ovarian stimulation in poor ovarian responders, and second, to address the controversies on the dosage of gonadotropins for this specific in vitro fertilization population. SAGE Publications 2021-06-27 /pmc/articles/PMC8243085/ /pubmed/34263173 http://dx.doi.org/10.1177/26334941211024203 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle New insights into ART/IVF in Poor Ovarian Responders
Boudry, Liese
Racca, Annalisa
Tournaye, Herman
Blockeel, Christophe
Type and dose of gonadotropins in poor ovarian responders: does it matter?
title Type and dose of gonadotropins in poor ovarian responders: does it matter?
title_full Type and dose of gonadotropins in poor ovarian responders: does it matter?
title_fullStr Type and dose of gonadotropins in poor ovarian responders: does it matter?
title_full_unstemmed Type and dose of gonadotropins in poor ovarian responders: does it matter?
title_short Type and dose of gonadotropins in poor ovarian responders: does it matter?
title_sort type and dose of gonadotropins in poor ovarian responders: does it matter?
topic New insights into ART/IVF in Poor Ovarian Responders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243085/
https://www.ncbi.nlm.nih.gov/pubmed/34263173
http://dx.doi.org/10.1177/26334941211024203
work_keys_str_mv AT boudryliese typeanddoseofgonadotropinsinpoorovarianrespondersdoesitmatter
AT raccaannalisa typeanddoseofgonadotropinsinpoorovarianrespondersdoesitmatter
AT tournayeherman typeanddoseofgonadotropinsinpoorovarianrespondersdoesitmatter
AT blockeelchristophe typeanddoseofgonadotropinsinpoorovarianrespondersdoesitmatter